Omeprazole
- Generic Name
- Omeprazole
- Brand Names
- Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 73590-58-6
- Unique Ingredient Identifier
- KG60484QX9
- Background
Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approva...
- Indication
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
...
- Associated Conditions
- Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
- Associated Therapies
- -
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 39
- Registration Number
- NCT01596647
- Locations
- 🇺🇸
Comprehensive Cancer Centers, Las Vegas, Nevada, United States
🇺🇸University of Kansas Cancer Center Medical Center, Kansas City, Kansas, United States
🇺🇸Henry Ford Hospital Henry Ford, Detroit, Michigan, United States
Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients
- Conditions
- Interventions
- First Posted Date
- 2012-05-08
- Last Posted Date
- 2015-08-17
- Lead Sponsor
- Zagazig University
- Target Recruit Count
- 70
- Registration Number
- NCT01593592
- Locations
- 🇪🇬
Zagazig University Hospitals, Zagazig, Sharkia, Egypt
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
- Conditions
- Interventions
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT01585623
- Locations
- 🇺🇸
Investigational Site Number 840004, Augusta, Georgia, United States
🇺🇸Investigational Site Number 840002, Philadelphia, Pennsylvania, United States
🇺🇸Investigational Site Number 840001, Detroit, Michigan, United States
Development of Minidose Inje Cocktail Method for Simultaneous Evaluating Five Cytochrome P450 Isoforms in Human
- Conditions
- Interventions
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2012-04-04
- Lead Sponsor
- Inje University
- Target Recruit Count
- 26
- Registration Number
- NCT01570569
Melatonin Associated to Acid Inhibition for Chemoprevention in Barret Esophagus: a Pilot Study
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Aragon Institute of Health Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT01566474
- Locations
- 🇪🇸
Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib
- Conditions
- Interventions
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 34
- Registration Number
- NCT01539655
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 28
- Registration Number
- NCT01517399
- Locations
- 🇺🇸
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
- Conditions
- Interventions
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 495
- Registration Number
- NCT01499368
Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2013-08-13
- Lead Sponsor
- Norgine
- Target Recruit Count
- 239
- Registration Number
- NCT01493089
- Locations
- 🇵🇱
Department of Gastroenterology and Hepatology, Oncology Centre, Roentgena, Warsaw, Poland
Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)
- Conditions
- Interventions
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT01470690
- Locations
- 🇳🇱
Crcn, Runmc, Nijmegen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.